Smoking causes cancer, but it could protect against Parkinson’s disease. This has been demonstrated by various epidemiological studies, according to which there exists an inverse relationship between smoking and the probability of developing Parkinson’s disease.
The link is not however 100% clear, as some smokers develop the illness nevertheless. The hypothesis is that there is a genetic predisposition that, in combination with environmental factors, can trigger the disease. Taking this as its starting point, a team from the Mayo Clinic in Rochester, MN (USA) has carried out a study on a sample of 1228 subjects. The team includes Maurizio Facheris, a researcher at the Institute of Genetic Medicine at the European Academy of Bozen/Bolzano (EURAC), previous Research Fellow at the prestigious American clinic and who co-ordinated the study.
The researchers hypothesized that the variation may be due to pharmacogenetic effects and that nicotine might have neuroprotective properties for certain individuals.
“We asked the interviewees to tell us about their relationship with smoking and then compared this data with the presence or absence of variations in the gene CYP2A6, which encodes the enzyme responsible for metabolising nicotine”, says EURAC researcher Maurizio Facheris, neurologist at the Department of Neurology of Bozen/Bolzano Central Hospital and main author of the study.
From an analysis of the data, it emerges that the presence of a particular variant of the gene, when combined with smoking, considerably reduces the risk of contracting Parkinson’s disease. It remains to be clarified whether the protection against the disease is provided by the particular variant of gene CYP2A6 or by the presence of cotinine, the substance into which nicotine is transformed through the action of the gene. “If this second hypothesis is confirmed, producing a cotinine-based drug would be a means to reduce exposure to the disease”, explains Maurizio Facheris.The study opens up interesting scenarios in the field of pharmacogenetics, a discipline that holds that variations in different patients’ response to pharmacological treatment depends on genetic factors. Under this view, analysing the patients’ DNA will allow us to predict their reaction to a particular drug and thus enable the development of personalised medicines.
The study was presented at Toronto on the occasion of the annual convention of the American Academy of Neurology, and was selected as among the top 5% of over 2,000 articles received. It was the first study of its kind to be presented.
Laura Defranceschi | idw
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Physics and Astronomy
08.12.2016 | Health and Medicine
08.12.2016 | Life Sciences